- Conference Call Scheduled for Tuesday, May 9, 2017 at 4:30pm ET -
NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced that the company will release first quarter
2017 financial results on Tuesday, May 9, 2017 after the close of
market. Revance will host a corresponding conference call and a
live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the
results and provide a business and pipeline update.
Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 3251601; or from the
webcast link in the investor relations section of the company's website
A replay of the call will be available beginning May 9, 2017 at 4:30pm
PT/7:30pm ET to May 10, 2017 at 4:30pm PT/7:30pm ET. To access the
replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference
ID: 3251601. The webcast will be available in the investor relations
section on the company's website for 30 days following the completion of
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology, orthopedics and neurology. Revance's
science is based upon a proprietary peptide technology, which when
combined with active drug molecules, may help address current unmet
needs. Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis with the potential to be
the first long-acting neuromodulator. The company holds worldwide rights
for all indications of RT002 injectable and RT001 topical and the
pharmaceutical uses of its proprietary peptide technology platform. More
information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks
of Revance Therapeutics, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006046/en/
Jeanie Herbert, 714-325-3584
Ami Bavishi, 212-213-0006
Nadine Tosk, 504-453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media